Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Autobio Forms $19 Million China IVD JV with Mobidiag and Invests $11.4 Million in the Company

publication date: Dec 19, 2018

Autobio Diagnostics, a Zhengzhou IVD company, will form a $19 million JV with Finland's Mobidiag to bring Mobidiag's Novodiag^® platform to China. The platform offers assays for human infectious disease, and the JV will focus initially on assays to detect respiratory and gastroenteric infections and meningitis. Autobio will contribute $14 million for a 65% stake in the JV, while Mobidiag will add $5 million for the rest. In addition, Autobio will make a $11.4 million investment in Mobidiag, though Autobio stressed the transaction was separate from the JV deal. More details....

Stock Symbol: (SHA: 603658)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.